These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18884684)

  • 41. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of heparin on the early stages of blood coagulation.
    O'BRIEN JR
    J Clin Pathol; 1960 Mar; 13(2):93-8. PubMed ID: 14428016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon.
    Felli A; Zeidler P; Jilma B; Opfermann P; Holaubek C; Zimpfer D; Wadowski PP; Steinlechner B
    J Cardiothorac Vasc Anesth; 2016 Jan; 30(1):96-101. PubMed ID: 26613641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of inhaled heparin on lung function and coagulation in healthy volunteers.
    Bendstrup KE; Gram J; Jensen JI
    Eur Respir J; 2002 Apr; 19(4):606-10. PubMed ID: 11998987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anticoagulant treatment with intravenous administration of heparin. Criteria of establishment of the dosage and rhythm of administration].
    Stoichiţă-Papilian M; Creţescu R
    Stud Cercet Med Interna; 1972; 13(1):53-62. PubMed ID: 5022326
    [No Abstract]   [Full Text] [Related]  

  • 47. [Studies on the fibrinolytic action of heparin substance in man].
    De Nicola P; Gibelli A; Turazza G; Nadile L
    Arzneimittelforschung; 1965 Dec; 15(12):1430-3. PubMed ID: 4225447
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of the sensitivity of an in vitro high frequency ultrasound device to monitor the coagulation process: study of the effects of heparin treatment in a murine model.
    Callé R; Rochefort GY; Desbuards N; Plag C; Antier D; Ossant F
    Ultrasound Med Biol; 2010 Feb; 36(2):295-305. PubMed ID: 20045589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EFFECT OF ADENOSINE NUCLEOTIDES ON PLATELET AGGREGATION AND CLOTTING TIME.
    MUSTARD JF; HEGARDT B; ROWSELL HC; MACMILLAN RL
    J Lab Clin Med; 1964 Oct; 64():548-59. PubMed ID: 14233144
    [No Abstract]   [Full Text] [Related]  

  • 50. Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins to man.
    Lane DA; MacGregor IR; VanRoss M; Cella G; Kakkar VV
    Thromb Res; 1979; 16(5-6):651-62. PubMed ID: 524315
    [No Abstract]   [Full Text] [Related]  

  • 51. The influence of temperature upon the heparin and citrate clotting times.
    LOSNER S; VOLK BW
    Am J Med Sci; 1953 Jul; 226(1):60-4. PubMed ID: 13065283
    [No Abstract]   [Full Text] [Related]  

  • 52. Heparin activity monitoring during vascular surgery.
    Jacobsen W; Brauer F; Smith LL
    Am J Surg; 1978 Jul; 136(1):141-4. PubMed ID: 677381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors Influencing ACT After Intravenous Bolus Administration of 100 IU/kg of Unfractionated Heparin During Cardiac Catheterization in Children.
    Muster I; Haas T; Quandt D; Kretschmar O; Knirsch W
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):740-747. PubMed ID: 27514640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Monitoring heparin therapy].
    Wettendorff P
    Rev Med Brux; 1983 Jan; 4(1):27-31. PubMed ID: 6836204
    [No Abstract]   [Full Text] [Related]  

  • 55. Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald D
    Perfusion; 2009 Mar; 24(2):97. PubMed ID: 19654151
    [No Abstract]   [Full Text] [Related]  

  • 56. The activated partial thromboplastin time as a monitor of heparin therapy: a warning.
    Makary AZ; Waterbury L
    Johns Hopkins Med J; 1977 Jun; 140(6):311-5. PubMed ID: 864903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of simultaneous administration of low-dose heparin and acetylsalicylic acid on blood coagulation and platelet functions.
    Loew D; Vinazzer H
    Haemostasis; 1974; 3(5-6):319-28. PubMed ID: 4468231
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of tests for heparin control during long-term extracorporeal circulation.
    Uziel L; Cugno M; Cacciabue E; Colombo A; Stabilini R; Mascheroni D; Agostoni A
    Int J Artif Organs; 1986 Mar; 9(2):111-6. PubMed ID: 3699906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Heparin level and coagulation potential after subcutaneous injection of 7500 international units of heparin calcium].
    Briel RC
    Dtsch Med Wochenschr; 1984 Jun; 109(25):993-6. PubMed ID: 6734457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.